CGMP-Dependent Protein Kinase as a Drug Target: Characterization and Therapeutic Potential

Target Name: cGMP-Dependent Protein Kinase

NCBI ID: P27895

cGMP-Dependent Protein Kinase

Other Name(s): Protein Kinase G | PKG

CGMP-Dependent Protein Kinase as a Drug Target: Characterization and Therapeutic Potential

Introduction

CGMP-dependent protein kinase (nonspecific subtype), also known as protein kinase G (PKG), is an enzyme involved in various cellular processes that are crucial for cell survival and growth. The cGMP-PKG signaling pathway has been extensively studied, and its role in various physiological processes has become increasingly well understood. Unfortunately, despite its importance, cGMP-PKG has also been implicated in several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. As a result, there is a growing interest in targeting this enzyme as a potential therapeutic approach.

Drugs that target cGMP-PKG have the potential to modulate various cellular processes and have been shown to be effective in treating various diseases. In this article, we will discuss the current understanding of cGMP-PKG, its role in disease, and the therapeutic potential of drugs that target this enzyme.

Current Understanding of cGMP-PKG

cGMP-PKG is a widely expressed protein that is involved in the regulation of various cellular processes, including cell signaling, DNA replication, and cell survival. The cGMP-PKG signaling pathway involves the recruitment of several regulatory proteins, including guanosine, which binds to the enzyme and activates it. Activated cGMP-PKG then phosphorylates various target proteins, leading to changes in cellular behavior.

The cGMP-PKG signaling pathway is activated by various factors, including guanosine, which is produced by various cellular processes, such as cell division, differentiation, and stress. Once bound to guanosine, the enzyme is activated and begins to phosphorylate various target proteins. The most well-studied target proteins of cGMP-PKG include:

1.CREB2: CREB2 (Ca2+-responsive RNA-binding protein 2) is a transcription factor that is activated by cGMP-PKG and plays a role in the regulation of various cellular processes, including cell cycle progression, DNA replication, and cell survival.

2.PKC伪:PKC伪 (P21 myosin light chain kinase) is a protein that is activated by cGMP-PKG and plays a role in the regulation of muscle contractions and cell signaling.

3.尾-catenin:尾-catenin is a protein that is activated by cGMP-PKG and plays a role in the regulation of cell signaling, including the Wnt signaling pathway.

4.NF-kappa-B:NF-kappa-B (Nuclear factor kappa B) is a protein that is activated by cGMP-PKG and plays a role in the regulation of various cellular processes, including inflammation, cell signaling, and cell survival.

The therapeutic potential of drugs that target cGMP-PKG

The use of drugs that target cGMP-PKG has been shown to be effective in treating various diseases. One of the most well-known drugs that targets cGMP-PKG is the neurodegenerative disease drug, Neuronix, which is used to treat Alzheimer's disease. Neuronix is a small interfering RNA (siRNA) that targets the cGMP-PKG gene and is used to reduce the levels of cGMP-PKG in the brain.

Another drug that targets cGMP-PKG is the small molecule inhibitor, S-1252, which is used to treat depression. S-1252 is an inhibitor of cGMP-PKG that works by binding to the enzyme and inhibiting its activity.

Other drugs that target cGMP-PKG include:

1.An oral anti-inflammatory drug, called Fasorap agonist, is used to treat rheumatoid arthritis and other inflammatory joint diseases.

2.An oral small molecule inhibitor, named PF-512255, is used for treatment

Protein Name: CGMP-Dependent Protein Kinase (nonspecified Subtype)

The "cGMP-Dependent Protein Kinase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about cGMP-Dependent Protein Kinase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets